'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients

被引:124
作者
Zanen, AL
Adriaansen, HJ
vanBommel, EFH
Posthuma, R
deJong, GMT
机构
[1] DRECHTSTEDEN HOSP,DEPT INTERNAL MED,DORDRECHT,NETHERLANDS
[2] DRECHTSTEDEN HOSP,DEPT CLIN CHEM,DORDRECHT,NETHERLANDS
[3] DRECHTSTEDEN HOSP,DEPT PHARMACOL,DORDRECHT,NETHERLANDS
关键词
ferric gluconate; haemodialysis; intravenous iron; iron toxicity;
D O I
10.1093/oxfordjournals.ndt.a027405
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Chronic haemodialysis causes blood loss and iron-deficiency. This can be corrected with intravenous preparations, e.g. sodium ferric-gluconate (FeGl). In two patients complaints of hypotension and malaise during FeGl infusion coincided with high levels of serum iron and a calculated transferrin iron saturation above 100%. Iron toxicity could be the cause of these complaints, Free iron is known to aggravate the toxicity of free radicals and other reactive oxygen products that are constantly formed in the body. We compared four rates of FeGl infusion with regard to iron parameters. Methods. 20 dialysis patients received a total of 36 infusions of FeGl. A rapid infusion of 125 mg (Protocol A (n=10)) or 62.5 mg (Protocol B (n=7)) of FeGl was given during the last 30 min of dialysis. A slow infusion of 125 mg (Protocol C (n=9)) or 62.5 mg (Protocol D (n=10)) was given during 4 or 4.5 h of dialysis. Blood was taken at regular intervals before, during, and after dialysis for determination of serum iron, transferrin, ferritin, haematocrit, total protein, albumin, and lactate dehydrogenase (LDH). Transferrin saturation was calculated from transferrin and serum iron. Results. With rapid infusion A (125 mg) the highest levels of serum iron (median 120 (range 40-159) micromol/l) and transferrin saturation (207 (84-331)%) were seen at the end of the infusion, These were significantly higher than the peak levels with B, C, and D (P less than or equal to 0.03). With rapid infusion B (62.5 mg), peak levels were intermediately high (serum Iron 61 (50-96) mu mol/l; transferrin saturation 118 (91-174)%). With slow infusion C(125 mg) similar peak levels were seen (serum iron 83 (43-106) mu mol/l; transferrin saturation 141 (88-172)%). With slow infusion D (62.5 mg), the lowest peak levels were seen (serum iron 38 (31-55) mu mol/l; transferrin saturation 78 (43-92)%). These levels were significantly lower than those with A, B and C (P less than or equal to 0.002). Only with D all patients showed a transferrin saturation lower than 100%. Ferritin was increased before the next dialysis in all patients. LDH was not significantly elevated during any infusion. Conclusions. The commonly used rapid infusion rate (A) of FeGl causes 'oversaturation' of transferrin. This is compatible with iron toxicity due to free iron which may explain our patients' complaints. Free iron cannot be measured directly. LDH as a crude measure of cell damage was not elevated. Better measurements to prove free iron toxicity, like lipid peroxides, are not yet readily available. Infusion during a longer period at a lower dose (D) is effective and eliminates 'oversaturation' of transferrin and probably the danger of iron toxicity.
引用
收藏
页码:820 / 824
页数:5
相关论文
共 20 条
[1]   IRON-DEFICIENCY IN MAINTENANCE HEMODIALYSIS-PATIENTS - ASSESSMENT OF DIAGNOSIS CRITERIA AND OF 3 DIFFERENT IRON TREATMENTS [J].
ALLEGRA, V ;
MENGOZZI, G ;
VASILE, A .
NEPHRON, 1991, 57 (02) :175-182
[2]   OXYGEN FREE-RADICALS AND HUMAN-DISEASES [J].
ARUOMA, OI ;
KAUR, H ;
HALLIWELL, B .
JOURNAL OF THE ROYAL SOCIETY OF HEALTH, 1991, 111 (05) :172-177
[3]  
AUERBACH M, 1988, J LAB CLIN MED, V111, P566
[4]   REDUCTION IN RECOMBINANT-HUMAN-ERYTHROPOIETIN DOSES BY THE USE OF CHRONIC INTRAVENOUS IRON SUPPLEMENTATION [J].
FISHBANE, S ;
FREI, GL ;
MAESAKA, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (01) :41-46
[5]  
GEISSER P, 1992, ARZNEIMITTEL-FORSCH, V42-2, P1439
[6]  
GOKAL R, 1979, Q J MED, V48, P369
[7]   IDENTIFICATION OF MALONDIALDEHYDE AS THE TBA-REACTANT FORMED BY BLEOMYCIN-IRON FREE-RADICAL DAMAGE TO DNA [J].
GUTTERIDGE, JMC .
FEBS LETTERS, 1979, 105 (02) :278-282
[8]  
GUTTERIDGE JMC, 1989, CLIN HAEMATOL, V2, P195
[9]   INTRAVENOUS IRON DEXTRAN IN CLINICAL MEDICINE [J].
HAMSTRA, RD ;
BLOCK, MH ;
SCHOCKET, AL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1980, 243 (17) :1726-1731
[10]  
HENDERSON PA, 1969, BLOOD-J HEMATOL, V34, P357